Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis

Area of Science:

• Immunology
• Nephrology
• Pharmacology

Background:

• Semaphorin3A (sema3A) exhibits established immune regulatory properties in innate and adaptive immunity.
• Previous studies demonstrated sema3A's efficacy in attenuating clinical symptoms and inflammation in a rheumatoid arthritis mouse model.

Purpose of the Study:

• To evaluate the therapeutic potential of semaphorin3A (sema3A) in a murine model of lupus nephritis.
• To assess the impact of sema3A on disease progression and survival in female NZB/W mice.

Main Methods:

• Forty-eight female NZB/W mice were divided into prevention (n=30) and treatment (n=18) groups.
• Semaphorin3A (sema3A) or an empty vector was administered via injection at different disease stages (prevention at week 12, treatment at proteinuria onset).

Main Results:

• Pre-emptive sema3A administration delayed proteinuria onset (110 days vs. 63 days) and prevented glomerular immune complex deposition.
• Treatment with sema3A in mice with established proteinuria increased survival rates and slowed disease deterioration.
• Renal damage was significantly reduced in sema3A-treated groups.

Conclusions:

• Semaphorin3A (sema3A) demonstrates significant therapeutic benefits in mitigating lupus nephritis in NZB/W mice.
• sema3A effectively delays proteinuria, reduces renal pathology, and enhances survival.
• The findings support further investigation into sema3A as a potential treatment for lupus nephritis, involving both innate and adaptive immune responses.